Revolution Medicines (RVMD) Consolidated Net Income (2019 - 2026)
Revolution Medicines (RVMD) posted Consolidated Net Income of -$644.4 million for Q2 2026, down 41.99% on a QoQ basis from -$453.8 million in Q1 2026, and down 160.05% year-over-year from $1.1 billion in Q2 2025.
Powered by 
Analysis
Revolution Medicines (RVMD) Consolidated Net Income (2019 - 2026) Analysis & Trends
Revolution Medicines has reported Consolidated Net Income for 8 years, with the latest figure at -$644.4 million in Q2 2026.
- On a quarterly basis, Consolidated Net Income fell 160.05% year-over-year to -$644.4 million in Q2 2026; TTM through Jun 2026 was -$1.8 billion, a 117.77% decrease from a year earlier, with the FY2025 full-year figure at -$893.7 million, down 48.94% from the prior year.
- Consolidated Net Income was -$644.4 million for Q2 2026 at Revolution Medicines, down from -$453.8 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$56.5 million in Q4 2022, with the low at -$644.4 million in Q2 2026.
- Average Consolidated Net Income over 5 years is -$195.3 million, with a median of -$144.8 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Consolidated Net Income slipped 7.27% in 2022, then plunged 187.27% in 2023.
- Over 5 years, Consolidated Net Income stood at -$56.5 million in 2022, then sank by 187.27% to -$162.3 million in 2023, then decreased by 19.83% to -$194.5 million in 2024, then plunged by 87.58% to -$364.9 million in 2025, then tumbled by 76.59% to -$644.4 million in 2026.
- The last three Consolidated Net Income figures came in at -$644.4 million (Q2 2026), -$453.8 million (Q1 2026), and -$364.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | 3.09 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | -238.00 Mn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 1.10 Bn |
| 10 | Revolution Medicines | 40.86 Bn | 40.86 Bn | - | -644.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -644.37 Mn |
| Mar 31, 2026 | -453.82 Mn |
| Dec 31, 2025 | -364.89 Mn |
| Sep 30, 2025 | -305.21 Mn |
| Jun 30, 2025 | -247.79 Mn |
| Mar 31, 2025 | -213.42 Mn |
| Dec 31, 2024 | -194.52 Mn |
| Sep 30, 2024 | -156.29 Mn |
| Jun 30, 2024 | -133.23 Mn |
| Mar 31, 2024 | -116.00 Mn |
| Dec 31, 2023 | -162.33 Mn |
| Sep 30, 2023 | -108.43 Mn |
| Jun 30, 2023 | -98.30 Mn |
| Mar 31, 2023 | -68.10 Mn |
| Dec 31, 2022 | -56.51 Mn |
| Sep 30, 2022 | -73.33 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -57.65 Mn |
| Dec 31, 2021 | -52.68 Mn |
| Sep 30, 2021 | -52.94 Mn |
API Access
Revolution Medicines Consolidated Net Income API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=RVMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "consolidated-net-income", "ticker": "RVMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=RVMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();